Sonoma Pharma's Revenue Jumps, But Cash Drains Amidst Mounting Losses

TL;DR

**SNOA's revenue is up, but their cash is burning fast, making it a risky bet unless they secure new funding ASAP.**

AI Summary

Sonoma Pharmaceuticals, Inc. (SNOA) reported a net loss of $534,000 for the three months ended September 30, 2025, an improvement from a net loss of $610,000 in the prior year period. For the six months ended September 30, 2025, the net loss was $1,775,000, slightly higher than the $1,753,000 loss for the same period in 2024. Revenue significantly increased to $5,604,000 for the three months ended September 30, 2025, up from $3,579,000 in 2024, and to $9,619,000 for the six months, compared to $6,970,000 in 2024. Despite revenue growth, the company's cash and cash equivalents decreased from $5,374,000 at March 31, 2025, to $3,035,000 at September 30, 2025. Net cash used in operating activities for the six months ended September 30, 2025, surged to $2,650,000 from $558,000 in the prior year, primarily due to increases in accounts receivable, inventories, and prepaid expenses. The company's accumulated deficit reached $199,581,000, and management expressed substantial doubt about its ability to continue as a going concern.

Why It Matters

Sonoma Pharmaceuticals' significant revenue growth of 56.5% for the quarter is a positive signal for its product commercialization efforts, but the substantial increase in cash burn from operations, up 374% year-over-year, raises serious liquidity concerns for investors. The company's explicit 'going concern' warning indicates a high risk of needing further capital, which could dilute existing shareholders or lead to operational cutbacks. Competitors in the wound care and dermatological markets, particularly those with stabilized hypochlorous acid products, may see an opportunity to gain market share if Sonoma struggles to secure financing and scale its operations effectively. Employees face uncertainty regarding job security, and customers could experience disruptions if the company's financial health deteriorates further.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern within one year' due to a history of losses and significant cash burn. Net cash used in operating activities increased from $558,000 in the six months ended September 30, 2024, to $2,650,000 in the same period of 2025, while cash and cash equivalents dropped from $5,374,000 to $3,035,000 over six months.

Analyst Insight

Investors should exercise extreme caution and consider divesting SNOA shares due to the explicit 'going concern' warning and rapid cash depletion. Potential investors should avoid initiating a position until the company demonstrates a clear path to profitability or secures substantial, non-dilutive financing to alleviate liquidity concerns.

Financial Highlights

debt To Equity

2.66

revenue

$9.619M

operating Margin

-14.9%

total Assets

$13.856M

total Debt

$10.069M

net Income

-$1.775M

eps

N/A

gross Margin

37.3%

cash Position

$3.035M

revenue Growth

+38%

Key Numbers

• $5.604M — Revenue for Q3 2025 (Increased from $3.579M in Q3 2024, a 56.5% increase.)
• $9.619M — Revenue for six months ended Sept 30, 2025 (Increased from $6.970M in the prior year, a 38% increase.)
• $534K — Net loss for Q3 2025 (Improved from a $610K net loss in Q3 2024.)
• $1.775M — Net loss for six months ended Sept 30, 2025 (Slightly higher than $1.753M in the prior year.)
• $3.035M — Cash and cash equivalents at Sept 30, 2025 (Decreased from $5.374M at March 31, 2025.)
• $2.650M — Net cash used in operating activities for six months ended Sept 30, 2025 (Increased significantly from $558K in the prior year.)
• $199.581M — Accumulated deficit at Sept 30, 2025 (Increased from $197.806M at March 31, 2025.)
• 1,701,076 — Shares outstanding as of Nov 3, 2025 (Reflects the impact of the August 29, 2024 reverse stock split.)

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Stock Market LLC (company) — exchange where SNOA is registered
• Invekra (company) — customer with a technical support contract
• Delaware (regulator) — state of incorporation
• Boulder, CO (person) — principal executive offices location

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has expressed substantial doubt about Sonoma Pharmaceuticals, Inc.'s ability to continue as a going concern. This is underscored by a significant increase in net cash used in operating activities to $2,650,000 for the six months ended September 30, 2025, up from $558,000 in the prior year, and a decrease in cash and cash equivalents from $5,374,000 to $3,035,000.
• Increasing Accumulated Deficit [high — financial]: The company's accumulated deficit has grown to $199,581,000 as of September 30, 2025. This persistent deficit indicates a history of net losses that have not been offset by profits, raising concerns about long-term financial viability.
• Inventory and Receivables Growth [medium — operational]: The surge in net cash used in operating activities is partly driven by increases in accounts receivable ($2,703,000 from $2,232,000) and inventories ($3,634,000 from $2,915,000). This suggests potential challenges in sales conversion or inventory management.
• Future Disclosure Requirements [low — regulatory]: The company will need to adopt ASU 2023-09, Income Taxes (Topic 740), for fiscal years beginning after December 31, 2024. This standard requires incremental disaggregation of income tax disclosures, which may involve additional compliance efforts.

Industry Context

Sonoma Pharmaceuticals operates in the pharmaceutical sector, which is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. The industry is competitive, with companies striving for innovation in drug discovery and commercialization. Trends include a focus on specialized therapeutics and increasing adoption of advanced manufacturing technologies.

Regulatory Implications

The company must comply with stringent FDA regulations for drug development and marketing. Future adoption of accounting standards like ASU 2023-09 will also require attention to disclosure requirements related to income taxes.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Analyze revenue drivers and gross margin sustainability.
3. Assess the company's ability to secure future financing.
4. Review management's strategy to address operating cash flow deficits.

Key Dates

• 2025-09-30: End of Second Fiscal Quarter — Reported net loss of $534,000 on $5.604M revenue, with cash and equivalents at $3.035M.
• 2025-03-31: End of Fiscal Year — Cash and equivalents were $5.374M, and accumulated deficit was $197.806M.
• 2024-08-29: Reverse Stock Split — Impacted the number of shares outstanding, which was 1,649,765 as of September 30, 2025.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income since its inception. (Indicates the company's historical unprofitability, reaching $199.581M.)

Going Concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Management has expressed substantial doubt about SNOA's ability to continue as a going concern.)

Operating Lease Liabilities

Obligations arising from leases where the lessee has the right to use an asset for a period but does not obtain ownership. (These liabilities increased significantly, with current portion at $88,000 and non-current at $391,000 as of September 30, 2025.)

Deferred Consideration

Payments to be made in the future for an acquisition or other transaction, often contingent on certain events or performance. (A portion of deferred consideration is classified as current ($204,000) and non-current ($0) as of September 30, 2025.)

Allowance for Obsolete and Excess Inventory

A contra-asset account that reduces the carrying value of inventory to its estimated net realizable value. (The allowance increased to $305,000 as of September 30, 2025, indicating potential issues with inventory valuation.)

Year-Over-Year Comparison

Compared to the prior year, Sonoma Pharmaceuticals has seen a significant increase in revenue, with a 56.5% rise in the third quarter and 38% for the six-month period. However, this top-line growth has not translated into improved profitability, as the net loss for the six months slightly increased. A major concern is the dramatic rise in net cash used in operating activities, which surged from $558,000 to $2,650,000, coupled with a substantial decrease in cash and cash equivalents. New risks related to lease obligations and inventory management have also emerged, contributing to the overall bearish sentiment.

Key Financial Figures

• $0.0001 — nge on Which Registered Common Stock, $0.0001 par value SNOA The Nasdaq Stock Marke

Filing Documents

• sonoma_i10q-093025.htm (10-Q) — 701KB
• sonoma_ex3101.htm (EX-31.1) — 8KB
• sonoma_ex3102.htm (EX-31.2) — 8KB
• sonoma_ex3201.htm (EX-32.1) — 4KB
• 0001683168-25-007938.txt ( ) — 3877KB
• snoa-20250930.xsd (EX-101.SCH) — 26KB
• snoa-20250930_cal.xml (EX-101.CAL) — 51KB
• snoa-20250930_def.xml (EX-101.DEF) — 83KB
• snoa-20250930_lab.xml (EX-101.LAB) — 277KB
• snoa-20250930_pre.xml (EX-101.PRE) — 224KB
• sonoma_i10q-093025_htm.xml (XML) — 493KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Unaudited Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Changes in Stockholders' Equity 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures (Not applicable.) 27 Item 5. Other Information 27 Item 6. Exhibits 28

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) September 30, 2025 March 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 3,035 $ 5,374 Accounts receivable, net 2,703 2,232 Inventories, net 3,634 2,915 Prepaid expenses and other current assets 2,925 1,915 Current portion of deferred consideration, net of discount 204 212 Total current assets 12,501 12,648 Property and equipment, net 284 225 Operating lease, right of use assets 479 84 Deferred tax asset, net 508 589 Deferred consideration, net of discount, less current portion – 73 Other assets 84 74 Total assets $ 13,856 $ 13,693 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,404 $ 953 Accrued expenses and other current liabilities 2,024 2,224 Deferred revenue, current portion 750 641 Short-term debt 56 220 Operating lease liabilities, current portion 88 58 Total current liabilities 4,322 4,096 Deferred revenue, net of current portion – 17 Withholding tax payable 5,356 5,142 Operating lease liabilities, less current portion 391 27 Total liabilities 10,069 9,282 Commitments and Contingencies (Note 5) – Stockholders' Equity: Convertible preferred stock, $ 0.0001 par value; 714,286 shares authorized at September 30, 2025 and March 31, 2025, no shares issued and outstanding at September 30, 2025 and March 31, 2025 – – Common stock, $ 0.0001 par value; 50,000,000 shares authorized at September 30, 2025 and March 31, 2025, 1,649,765 and 1,634,265 shares issued and outstanding at September 30, 2025 and March 31, 2025, respectively (Note 1) – – Additional paid-in capital 206,733 206,593 Accumulated deficit ( 199,581 ) ( 197,806 ) Accumulated other comprehensive loss ( 3,365 ) ( 4,376 ) Total stockholders' equity 3,787 4,411 Total liabilit

financial statements and footnotes

financial statements and footnotes. Recent Accounting Standards Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, establishes incremental disaggregation of income tax disclosure pertaining to the effective tax rate reconciliation and income taxes paid. This standard is effective for fiscal years beginning after December 31, 2024 and requires prospective application with the option to apply it retrospectively. The Company intends to adopt this standard in its Annual Report on Form 10-K for the year ended March 31, 2026. The Company is currently evaluating the potential impact of adopting the standard on its disclosures. This and other accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption. 10 Note 4. Condensed Consolidated Balance Sheet Inventories, net Inventories, net consist of the following: Schedule of inventories, net September 30, March 31, 2025 2025 Raw materials $ 1,974,000 $ 1,395,000 Finished goods 1,965,000 1,818,000 Inventories, gross 3,939,000 3,213,000 Less: allowance for obsolete and excess inventory ( 305,000 ) ( 298,000 ) Total inventories, net $ 3,634,000 $ 2,915,000 Leases The Company's operating leases are comprised primarily of facility leases. Balance sheet information related to the Company's leases is presented below: Schedule of lease information September 30, March 31, 2025 2025 Operating leases: Operating lease right-of-use assets $ 479,000 $ 84,000 Operating lease liabilities – current 88,000 58,000 Operating lease liabilities – non-current 391,000 27,000 Other information related to leases is presented below: Three Months Ended September 30, 2025 Operating lease cost $ 187,000 Other information: Ope

View Full Filing

View this 10-Q filing on SEC EDGAR